20
Participants
Start Date
October 31, 1995
Primary Completion Date
December 31, 2001
Study Completion Date
February 29, 2008
pyrazoloacridine
"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
Barbara Ann Karmanos Cancer Institute, Detroit
National Cancer Institute (NCI)
NIH
Barbara Ann Karmanos Cancer Institute
OTHER